Insmed (FRA:IM8N) Long-Term Debt : €1,053.7 Mil (As of Dec. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Insmed Long-Term Debt?

Insmed's Long-Term Debt for the quarter that ended in Dec. 2024 was €1,053.7 Mil.

Insmed's quarterly Long-Term Debt declined from Jun. 2024 (€879.6 Mil) to Sep. 2024 (€860.3 Mil) but then increased from Sep. 2024 (€860.3 Mil) to Dec. 2024 (€1,053.7 Mil).

Insmed's annual Long-Term Debt declined from Dec. 2022 (€1,062.2 Mil) to Dec. 2023 (€1,059.4 Mil) and declined from Dec. 2023 (€1,059.4 Mil) to Dec. 2024 (€1,053.7 Mil).

Insmed Long-Term Debt Historical Data

The historical data trend for Insmed's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insmed Long-Term Debt Chart

Insmed Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Debt

Get a 7-Day Free Trial

292.89

501.43

1,062.24

1,059.42

1,053.73

Insmed Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Long-Term Debt	Get a 7-Day Free Trial															1,059.42	863.96	879.60	860.30	1,053.73

Insmed (FRA:IM8N) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Insmed Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Insmed's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Insmed Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (FRA:IM8N) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

INSM:USA 0JAV:UK

Address

700 US Highway 202/206, Bridgewater, NJ, USA, 08807

Website

https://www.insmed.com

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Insmed Headlines

No Headlines